Tenofovir alafenamide

Tenofovir alafenamide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Healthy Volunteer、Weight Gain、Metabolic Effects、Integrase Strand Transfer Inhibitors。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Tenofovir alafenamide 研究

• Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels

  II 期招募中美国NCT07841990

• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  II 期招募中美国Argentina澳大利亚比利时NCT07202546

• Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)

  I 期 / II 期招募中中国NCT07711223

• A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

  II 期 / III 期招募中美国Argentina加拿大ChileNCT07266831

• REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

  IV 期招募中美国NCT07476339

• Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.

  不适用招募中中国NCT07169656

• Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

  IV 期招募中MexicoNCT07138144

• A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

  II 期招募中美国澳大利亚加拿大Puerto RicoNCT07645287

• Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

  II 期招募中美国NCT05652478

• Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma

  不适用招募中中国NCT07727642

• DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

  III 期招募中MexicoNCT07075146

• Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

  IV 期招募中中国NCT05182463

• Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

  不适用招募中中国NCT03920618

• Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B

  不适用招募中中国台湾NCT05583006

• Real-world Study Optimizing Nucleotide-analogues

  不适用招募中中国NCT05937178

• Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

  IV 期招募中MexicoNCT07031063

• Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads

  不适用招募中中国NCT06947356

• ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

  IV 期招募中中国NCT07573943

• Safety and Efficacy of TAF to Prevent MTCT of HBV in Middle/Late Pregnancies With High HBV DNA Load

  不适用招募中中国NCT05466071

• Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

  II 期 / III 期招募中美国加拿大Puerto RicoNCT07708727

• Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）

  不适用招募中中国NCT06323681

• Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

  不适用招募中中国NCT04231565

• Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women

  IV 期招募中中国NCT05853718

• TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.

  不适用招募中IndiaNCT05195450

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。